Clinical Trial Update: Study Of GW679769 In Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of GW679769 for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GW679769

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED